tmc310911
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00838760)
Timeline
Indications
Mechanism of action
- ProteaseINHIBITOR
protease inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tmc310911
- tmc310911
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04547894 | Phase 1 | Nov 1, 2020 | Ascletis Pharmaceuticals Co., Ltd., Capital Medical University |
| NCT04261907 | N/A | Feb 7, 2020 | Ascletis Pharmaceuticals Co., Ltd., Zhejiang University |
| NCT04261270 | Phase 3 | Feb 1, 2020 | Huazhong University of Science and Technology |
| NCT00838162 | Phase 2 | Jun 1, 2009 | Tibotec |
| NCT00908414 | Phase 1 | May 1, 2009 | Tibotec |
| NCT00838760 | Phase 1 | Feb 1, 2009 | Tibotec |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tibotec | For profit | 3 | 3 | 2 | 2009 |
| Ascletis Pharmaceuticals Co., Ltd. | For profit | 2 | 1 | 2 | 2020 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1